Deleterious Effect of Advanced CKD on Glyoxalase System Activity not Limited to Diabetes Aetiology

Autor: Anna Pleskačová, Katarína Chalásová, Kateřina Kaňková, Jitka Řehořová, Lukáš Pácal, Josef Tomandl
Rok vydání: 2018
Předmět:
Male
0301 basic medicine
glyoxalase
lcsh:Chemistry
Diabetic nephropathy
chemistry.chemical_compound
Gene expression
Diabetic Nephropathies
lcsh:QH301-705.5
Spectroscopy
Whole blood
diabetes
chronic kidney disease
diabetic nephropathy
Methylglyoxal
Lactoylglutathione Lyase
General Medicine
Middle Aged
Pyruvaldehyde
3. Good health
Computer Science Applications
Female
medicine.medical_specialty
Renal function
Peripheral blood mononuclear cell
Article
Catalysis
Inorganic Chemistry
03 medical and health sciences
Internal medicine
Diabetes mellitus
Diabetes Mellitus
medicine
Humans
Renal Insufficiency
Chronic
Physical and Theoretical Chemistry
Molecular Biology
Aged
business.industry
Organic Chemistry
medicine.disease
030104 developmental biology
Endocrinology
lcsh:Biology (General)
lcsh:QD1-999
chemistry
Case-Control Studies
business
Glyoxalase system
Zdroj: International Journal of Molecular Sciences; Volume 19; Issue 5; Pages: 1517
International Journal of Molecular Sciences, Vol 19, Iss 5, p 1517 (2018)
International Journal of Molecular Sciences
ISSN: 1422-0067
Popis: Methylglyoxal production is increased in diabetes. Methylglyoxal is efficiently detoxified by enzyme glyoxalase 1 (GLO1). The aim was to study the effect of diabetic and CKD milieu on (a) GLO1 gene expression in peripheral blood mononuclear cells; (b) GLO1 protein levels in whole blood; and (c) GLO1 activity in RBCs in vivo in diabetic vs. non-diabetic subjects with normal or slightly reduced vs. considerably reduced renal function (CKD1-2 vs. CKD3-4). A total of 83 subjects were included in the study. Gene expression was measured using real-time PCR, and protein levels were quantified using Western blotting. Erythrocyte GLO1 activity was measured spectrophotometrically. GLO1 gene expression was significantly higher in subjects with CKD1-2 compared to CKD3-4. GLO1 protein level was lower in diabetics than in non-diabetics. GLO1 activity in RBCs differed between the four groups being significantly higher in diabetics with CKD1-2 vs. healthy subjects and vs. nondiabeticsfig with CKD3-4. GLO1 activity was significantly higher in diabetics compared to nondiabetics. In conclusion, both diabetes and CKD affects the glyoxalase system. It appears that CKD in advanced stages has prevailing and suppressive effects compared to hyperglycaemia. CKD decreases GLO1 gene expression and protein levels (together with diabetes) without concomitant changes of GLO1 activity.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje